Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction
| Autor: | Henk-Jan Guchelaar, J. M. Baas, Gilles Paintaud, L. L. Krens, Hans Gelderblom, Céline Desvignes, Michiel C. Verboom |
|---|---|
| Přispěvatelé: | Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center (LUMC), Department of Clinical Oncology, Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017] (GICC UMR 7292 CNRS), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment [SDV]Life Sciences [q-bio] Cetuximab Antineoplastic Agents Bone Neoplasms Toxicology Antibodies Monoclonal Humanized 03 medical and health sciences Impaired renal function 0302 clinical medicine Pharmacokinetics Renal Dialysis Internal medicine medicine Humans Pharmacology (medical) Renal Insufficiency neoplasms 030304 developmental biology Aged Pharmacology 0303 health sciences Chemotherapy Osteosarcoma business.industry Compassionate Use medicine.disease 3. Good health Renal dysfunction *Pharmacokinetics 030220 oncology & carcinogenesis Metastatic osteosarcoma Monoclonal [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology Renal dysfunction business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology, 73(6), 1303-1306 Cancer Chemotherapy and Pharmacology Cancer Chemotherapy and Pharmacology, Springer Verlag, 2014, epub ahead of print. ⟨10.1007/s00280-014-2462-4⟩ |
| ISSN: | 0344-5704 1432-0843 |
| DOI: | 10.1007/s00280-014-2462-4⟩ |
| Popis: | International audience; INTRODUCTION: In the literature, data on the effect of renal impairment on the pharmacokinetics of anticancer drugs are scarce. Here, we report a 68-year-old metastatic osteosarcoma patient with impaired renal function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/m(2) cetuximab. MATERIAL AND METHODS: Pharmacokinetic parameters after the first dose, including dose-normalised AUC from time zero to day 7, clearance, elimination half-life (t 1/2), were estimated using trapezoidal non-compartmental methods and compared to pharmacokinetic data from a study population with normal kidney function. RESULTS: The results showed that the pharmacokinetics of cetuximab in this patient with renal failure was similar to that with adequate renal function. CONCLUSION: This study suggests that cetuximab can be safely used in cancer patients with renal impairment without dose adjustment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink